CO-DIAGNOSTICS INC
CODXNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $0.53 β $46.50
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 6.8M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $622,489
- Last Q Revenue
- $166,131
- P/E Ratio
- β
- P/S Ratio
- 5.9x
- EPS (TTM)
- $-23.84
- Dividend Yield
- β
- Dilution (1yr)
- +20.7%
CO-DIAGNOSTICS INC
CODXAbout CO-DIAGNOSTICS INC
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.